B7-H3 UCAR-T

B7-H3 UCAR-T is an investigational chimeric antigen receptor (CAR) T cell therapy designed to target the B7-H3 (CD276) antigen, a member of the human B7 family ligands. B7-H3 is highly and aberrantly expressed across a wide range of solid tumors—including glioblastoma, pediatric brain tumors, osteosarcoma, medulloblastoma, Ewing sarcoma, head and neck squamous cell carcinoma (HNSCC), triple negative breast cancer (TNBC), prostate cancer, intrahepatic cholangiocarcinoma (ICC), and pancreatic ductal adenocarcinoma—while showing limited expression in normal tissues[1][2][3][5]. The therapy involves engineering patient-derived or universal donor T cells to express a CAR that recognizes and binds to the B7-H3 antigen on tumor cells. Upon binding to its target on tumor cells, these modified T cells become activated and mediate cytotoxicity against the malignant tissue[1][2][5]. Preclinical studies have demonstrated significant antitumor activity in xenograft models of various solid tumors[1][5], while early-phase clinical trials are underway for recurrent glioblastoma multiforme (rGBM) and pediatric solid tumors[2][4]. The approach aims to overcome resistance mechanisms associated with cancer-initiating cells by targeting both differentiated tumor cells and cancer stem-like subpopulations expressing high levels of B7-H3[1][2][3].

Other names

B7-H3 CAR TB-7-H3 CAR TB 7-H3 CAR TB7-H3-targeted CAR T cell therapyB-7-H3-targeted CAR T cell therapyB 7-H3-targeted CAR T cell therapyTX103TX-103TX 103